Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
The DOI matches its Crossref record; 220 of the 221 references it cites were found in a registry or an index.
Abstract
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but concerns [13] have remained about supersensitivity psychosis [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“In the era of first-generation antipsychotics (FGAs) both supersensitivity psychosis and tardive dyskinesia were widely studied [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Chouinard et al. [9] described withdrawal reactions due to antipsychotics dose decrease, discontinuation, or switch and concluded that acute withdrawal symptoms, rebound, and persistent post-withdrawal disorders may occur”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Social Origins of Depression: A Study of Psychiatric Disorder in Women.
Schnitzer, P. K., Brown, G. W., & Harris, T. (1980) · Contemporary Sociology · doi:10.2307/2065631 · Cited by 3,053
A permanent change in brain function resulting from daily electrical stimulation
Goddard, G. V., McIntyre, D. C., & Leech, C. K. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90128-9 · Cited by 3,052
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Book Review: Measurement and Classification of Psychiatric Symptoms
Priest, R. G. (1975) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577506800751 · Cited by 2,262
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Research works printed but not linked: 1
- 10.2165/1120086-000000000-00000 · doi:10.2165/1120086-000000000-00000
Cited by
Items 101–200 of 270
What is the significance of the impact of antipsychotics on the gut microbiome?
Seeman, M. V. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2200161 · Cited by 10
“Long-term dysbiosis, such as that produced by long-term use of AP, leads to altered neurotransmitter levels (5-HT, dopamine, noradrenaline, and glutamate), altered signal transduction, increased inflammation and oxidative stress, and mitochondrial dysfunction, all of which can increase the severity of psychiatric symp…”
BackgroundIntervenir précocement dans les stades débutants du trouble bipolaire : pourquoi, quand et comment
Pouchon, A., Fakra, É., Haesebaert, F., Legrand, G., Rigon, M., Schmitt, E., Conus, P., Bougerol, T., Polosan, M., & Dondé, C. (2021) · L Encéphale · doi:10.1016/j.encep.2021.05.007 · Cited by 12
Preventing disease progression in schizophrenia: What are we waiting for
Lieberman, J. A., Mendelsohn, A. I., Goldberg, T. E., & Emsley, R. A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.042 · Cited by 11
Coutts‐Bain, D., Sharpe, L., Techakesari, P., Forrester, M., & Hunt, C. J. (2023) · Clinical Psychology Review · doi:10.1016/j.cpr.2023.102342 · Cited by 11
Yang, H., Peng, R., Yang, M. L., Zhang, J., Shi, Z., & Zhang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05621-6 · Cited by 11
“In addition, prolonged use of dopamine D2 receptor blockers may lead to hypersensitivity of dopamine receptors, which may increase the relapse rate after discontinuation of the drug [44].”
BackgroundCohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats
Kimura, M., Oda, Y., Oishi, K., Yoshino, K., Kimura, H., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.062 · Cited by 9
Self-citationClinical correlates of early onset antipsychotic treatment resistance
de Freitas, D. F., Agbedjro, D., Kadra-Scalzo, G., Francis, E., Ridler, I., Pritchard, M., Shetty, H., Segev, A., Casetta, C., Smart, S. E., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221132537 · Cited by 8
“Thus, the association of LAIs with late TRS, seen in the sensitivity analysis, is in line with the hypothesis that late TRS arises through dopamine supersensitivity following sustained high-dose, high-potency antipsychotic treatment (Chouinard et al., 2017).”
ResultKanahara, N., Hirabayashi, M., Mamada, T., Nishimoto, M., & Iyo, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.038 · Cited by 9
Self-citationBrown, R. W., Bhide, P. G., Gill, W. D., & Peeters, L. D. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05631-8 · Cited by 11
“Additionally, all effective antipsychotic drugs are D2-like receptor antagonists (Chouinard et al. 2017).”
BackgroundHelping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 11
“Dopamine super-sensitivity has also been linked to tardive dyskinesia and ‘ tolerance ’ or reduced ef fi cacy of antipsychotics 20 , exempli fi ed by studies fi nding relapse rates of 30% while on stable doses of medication in clinical populations 21,22 , predicted by the emergence of tardive…”
Kimura, M., Oda, Y., Hirose, Y., Kimura, H., Yoshino, K., Niitsu, T., Kanahara, N., Shirayama, Y., Hashimoto, K., & Iyo, M. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173288 · Cited by 8
Self-citationOishi, K., Kanahara, N., Takase, M., Oda, Y., Nakata, Y., Niitsu, T., Ishikawa, M., Sato, Y., & Iyo, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207133 · Cited by 8
Self-citationKing, S. R., Allan, M., & Lindsey, L. (2022) · Psychosis · doi:10.1080/17522439.2022.2141841 · Cited by 8
“No consensus exists over whether withdrawal effects are iatrogenic (Chouinard et al., 2017; Moncrieff, 2006), or whether the experiences are a relapse of a prior diagnosis (Emsley et al., 2018).”
BackgroundTibrewal, P., Nair, P. C., Gregory, K. J., LANGMEAD, C. J., Chan, S. K. W., & Bastiampillai, T. J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02026-x · Cited by 9
Takao, N., Murai, T., & Fujiwara, H. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242495 · Cited by 10
de Beer, F., de Vries, E. F. J., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., Gangadin, S. S., de Haan, L., Hamers, I. M. H., Veling, W., et al. (2025) · Psychological Medicine · doi:10.1017/s003329172510161x · Cited by 8
“Long-term exposure to antipsychotic treatment has been shown to alter pre-and postsynaptic dopamine neurotransmission and has been implied to upregulate D 2 R (Chouinard et al., 2017).”
The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy
Spangemacher, M., Schmitz, C. N., Cumming, P. D., Färber, L. V., Hart, X. M., Uchida, H., & Gründer, G. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03582-2 · Cited by 9
“This is especially relevant in the context of potential long-term side effects of excessive D 2 R antagonism, notably tardive dyskinesia [66] and super-sensitivity psychosis [67 – 69].”
Casulari, L. A., de Castro, L. F., Kessler, I. M., Mendonça, J. L., & Gonzaga, M. D. F. D. M. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2071-2 · Cited by 8
Fraguas, D., Almenta, D., Arques, S., Gómez‐Revuelta, M., Sánchez-Lafuente, C. G., Huerta, D. H., Arias, D. N., Plasencia-García, B. O., Parro-Torres, C., Guillena, S. L. R., et al. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2064308 · Cited by 9
“The latter may arise after interrupting or reducing the medication, or due to the administration of a dopamine agonist (Chouinard et al., 2017; Yin et al., 2021).”
BackgroundCosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7
Self-citationIs there rebound psychosis on withdrawal of antipsychotic medication in schizophrenia?
Taylor, M. J., & Yim, S. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.06.008 · Cited by 6
Liu, C., Liu, C.-M., Chien, Y., Lin, Y., Hsieh, M. H., Hwang, T., & Hwu, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.714878 · Cited by 7
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Barone, A., Vellucci, L., Ciccarelli, M., Matrone, M., Simone, G. D., Iannotta, F., Iasevoli, F., & de Bartolomeis, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178598 · Cited by 9
Crump, C., Abuelazm, H., Ibrahim, K., Shah, S. R., & El‐Mallakh, R. S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367695 · Cited by 7
“These changes can lead to complications such as tardive dyskinesia [50] and tardive psychosis or dopamine supersensitivity psychosis [51].”
Antipsychotic discontinuation and recovery: chicken or egg?
Pierre, J. M., Zito, M. F., Yang, Y. S., & Marder, S. R. (2021) · Psychological Medicine · doi:10.1017/s0033291721001872 · Cited by 6
“’s reference to the ‘supersensitivity psychosis’ hypothesis (Chouinard et al., 2017) that argues that clinicians mistake relapse for medication rebound effects is unsupported by empiric evidence and is contradicted by a time course of relapse that often takes weeks to months as well as equivalent relapse rates with ab…”
BackgroundCase series on aripiprazole and dopamine supersensitivity psychosis
Russell, G., Reinfeld, S., Kam, O., Lee, G., Weiss, M., & Koola, M. M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000391 · Cited by 7
“…of schizophrenia experienced marked worsening of psychosis meeting DSP diagnostic criteria shortly after abrupt switching to aripiprazole from a D2 receptor full antagonist – cases one, two and four worsening within 4 days and case three within 5 days (Chouinard, 1991; Chouinard et al., 2017).”
BackgroundInfluentialDrug-induced psychiatric disorders: A pharmacovigilance update
Montastruc, F., & de Laportalière, T. T. (2023) · Therapies · doi:10.1016/j.therap.2023.09.007 · Cited by 11
Hudnik, L. K., Blagus, T., Redenšek, S., Dolžan, V., Bon, J., & Pjevac, M. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1363051 · Cited by 8
Simon, N., & Azorin, J. (2018) · L Encéphale · doi:10.1016/j.encep.2018.10.003 · Cited by 8
Kanahara, N., Yoshimura, K., Nakamura, M., Oda, Y., Watanabe, M., & Iyo, M. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000257 · Cited by 7
Self-citationGenetic risks of schizophrenia identified in a matched case–control study
Oishi, K., Niitsu, T., Kanahara, N., Sato, Y., Iwayama, Y., Toyota, T., Hashimoto, T., Sasaki, T. G., Takase, M., Shiina, A., et al. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01158-3 · Cited by 6
Self-citationOlanzapine enhances early brain maturation through activation of the NODAL/FOXH1 axis
Teng, Z., Chen, Z., Zou, T., Su, Y., Zeng, H., Sun, S., Chen, H., Liu, J., Qin, Y., Wu, H., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110917 · Cited by 5
Antipsychotic-induced supersensitivity – A reappraisal
Lugg, W. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211025694 · Cited by 7
“Individuals in the Zipursky study had taken antipsychotics for an average 15 months prior to discontinuation – evidence suggests ‘supersensitisation’ may only take some 3 months (Chouinard et al., 2017; Silvestri et al., 2000).”
BackgroundFisher, K. A., Scemla, S., Villalba, C. L. A., & Kroin, J. (2022) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1395 · Cited by 5
Matsuzaka, Y., Noguchi, M., Kanamura, S., Maeda, K., Hisano, T., Tanaka, D., Ando, Y., Yamamoto, T., Morimoto, Y., Ozawa, H., et al. (2022) · Neurocase · doi:10.1080/13554794.2022.2114838 · Cited by 7
The relevance of long-acting injectables in the treatment of schizophrenia
Hahn, M., & Roll, S. C. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00033-0 · Cited by 5
Masumo, Y., Kanahara, N., Kogure, M., Yamasaki, F., Nakata, Y., & Iyo, M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000442 · Cited by 5
“In terms of the clinical course of patients with DSP, they generally have good initial responses to antipsychotic(s), especially in the first episodes of psychosis but then show gradual loss of efficacy over repeat relapses even with increases in dosage (Iyo et al., 2013; Chouinard et al., 2017).”
BackgroundSelf-citationYamasaki, F., Kanahara, N., Nakata, Y., Koyoshi, S., Yanagisawa, Y., Saito, T., Oiwa, T., Kogure, M., Sasaki, T. G., Yoshida, T., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231177268 · Cited by 6
“…in patients who have already developed DS, switching to a DPA may induce rebound psychosis and worsen psychotic symptoms, and DPAs may, therefore, be inappropriate for patients with DSP due to the high risk of failure when switching to these agents (Chouinard et al., 2017; Kanahara et al., 2021).”
BackgroundSelf-citationTakase, M., Kimura, H., Kanahara, N., Nakata, Y., & Iyo, M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119900982 · Cited by 6
“This state is characterized by rebound psychosis and/or tardive dyskinesia, conditions which are often observed in patients with schizophrenia under long-term treatment with high-dose antipsychotic(s) (Chouinard and Jones, 1980; Chouinard et al., 1978, 2017; Iyo et al., 2013).”
BackgroundSelf-citationMurata, T., 根岸大希, Yuki, K., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102845 · Cited by 5
Lormetazepam in oral solution: a formulation at risk of high-dose use
Cosci, F., Nardi, A. E., Starčević, V., Chouinard, G., & Balon, R. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02143-y · Cited by 5
Self-citationMa, C.-H., Chan, H., Hsieh, M. H., Liu, C., Liu, C., Hwu, H., Kuo, C., Chen, W. J., & Hwang, T. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211064396 · Cited by 4
Yang, C., Zhang, L., Liu, J., Li, K., Li, S., Yang, Z., Bishop, J. R., Deng, W., Yao, L., Lui, S., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae231 · Cited by 6
Clinical Implications of the Drug-Centered Approach
Steingard, S. (2018) · Springer eBooks · doi:10.1007/978-3-030-02732-2_5 · Cited by 5
Liu, C., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., & Hwu, H. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2440 · Cited by 4
“On the other hand, several medication discontinuation trials that endorsed maintenance therapy may have overestimated the risk of relapse, either discontinuing antipsychotics too fast, which rendered patients at risk of dopamine supersensitivity psychosis [29], or monitoring symptoms too closely after medication disco…”
Liu, C.-I., Liu, C., Chiu, H.-H., Chuang, C.-C., Hwang, T., Hsieh, M. H., Chien, Y., Lin, Y., Yen, K., & Liu, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724002356 · Cited by 4
“Because the abrupt discontinuation of antipsychotics potentially leads to dopamine supersensitivity psychosis (Chouinard et al., 2017; Moncrieff, 2015), a patient ’ s understanding and motivation to cooperate during the tapering process are important factors for successful dose reduction.”
BackgroundMetoclopramide-induced rapid-onset psychosis in a child with methylphenidate use: a case report
Ekici, G. İ., Dinç, G. Ş., & Kurt, A. N. Ç. (2024) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2024.5319 · Cited by 4
“17,24 Although dopamine supersensitivity is typically observed following prolonged use of antipsychotic medication, literature reports indicate that it can also occur in individuals without a prior history of psychosis, particularly after discontinuation of short half-life drugs like metoclopramide.”
Kaizer-Będkowska, M. J., & Kucia, K. A. (2018) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2018.0018 · Cited by 4
Tardive Dyskinesia: New Treatments Available
Limandri, B. J. (2019) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20190410-02 · Cited by 4
Nakajima, N., Mizoe, N., Misawa, F., Yamashita, T., So, R., Kitagawa, K., Tanimoto, K., Kishi, Y., 藤井, 康., & Takeuchi, H. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000347 · Cited by 4
“upregulation) following chronic treatment with antipsychotics, although the mechanism of DSP remains unclear (Chouinard et al., 2017).”
BackgroundRisk factors for early-phase clozapine discontinuation: A nested case-control study
Tsukiji, M., Sasaki, T. G., Nakata, Y., Ota, K., Aoki, T., Hara, K., Mamada, T., Nakane, J., Kogure, M., Seki, R., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102745 · Cited by 4
Self-citationEntstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen
Brandt, L., Henssler, J. F., & Gutwinski, S. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1293-6 · Cited by 4
“Das Thema Absetzphänomene bei psychiatri schen Medikamenten hat insbesondere in den letz ten Jahren zunehmende Beachtung in Klinik und Forschung erhalten [4, 8, 9, 10, 11, 12].”
BackgroundInfluentialLawrence, R. E., Appelbaum, P. S., & Lieberman, J. A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.022 · Cited by 5
Shakir, M., van Harten, P. N., Hoogendoorn, A. W., Willems, A. E., & Tenback, D. E. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.09.007 · Cited by 5
Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation
Oruch, R., Rajab, H. A., Elderbi, M., Pryme, I. F., Fasmer, O. B., & Lund, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228125 · Cited by 7
“Lipid-soluble long-acting injectable (LAI) APC preparations such as haloperidol de-canoate, paliperidone palmitate, LAI risperidone, and LAI olanzapine, which are designed to reduce hospitalization periods of patients, may cause DSS [45], although the issue is perplexing.”
Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches
Lim, D. X. E., Yeo, S. Y., Chia, Z. Y. A., Fernandis, A. Z., Lee, J., & Chua, J. J. E. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01375 · Cited by 13
Severe movement disorder and psychosis from haloperidol withdrawal in a 7‐year‐old girl with autism
Syamkumar, S., & Dossetor, D. R. (2020) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14848 · Cited by 3
Philip Seeman's contributions to the story of schizophrenia
Seeman, M. V. (2022) · Psychological Medicine · doi:10.1017/s0033291721004803 · Cited by 3
Langzeittherapie der Schizophrenie
Huhn, M., Schneider‐Thoma, J., & Leucht, S. (2022) · PSYCH up2date · doi:10.1055/a-1239-5941 · Cited by 3
Potla, S., AlQabandi, Y., Nandula, S. A., Boddepalli, C. S., Gutlapalli, S. D., Lavu, V. K., Abdelwahab, R. A. M., Huang, R., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.34746 · Cited by 5
“When they stay longer than six weeks, they are chronic post-withdrawal illnesses [24,25].”
Read, J. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12551 · Cited by 3
Quantitative evaluation of multiple treatment regimens for treatment-resistant depression
Feng, Y., Lv, Y., Yang, J., Xu, L., Chen, J., Huang, J., Ren, J., Zheng, Q., & Li, L. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf007 · Cited by 5
“27 Its broad receptor activity contributes to the regulation of mood, cognition, sleep, and appetite and can be used for combination therapy in TRD, especially in conjunction with fluoxetine 28 (OFC combination therapy), marketed under the trade name Symbyax, which has been approved by the FDA for…”
Genetic combination risk for schizophrenia
Oishi, K., Niitsu, T., Kanahara, N., Hashimoto, T., Komatsu, H., Sasaki, T. G., Takase, M., Sato, Y., & Iyo, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.021 · Cited by 3
Self-citationTowards personalized pharmacology: Antipsychotics and schizophrenia
Carton, L., Bordet, R., Montastruc, F., & Guilhaumou, R. (2020) · Therapies · doi:10.1016/j.therap.2020.12.010 · Cited by 5
Brandt, L., Montag, C., Bermpohl, F., Finck, A., Wieacker, E., Heinz, A., & Gutwinski, S. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113637 · Cited by 3
Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable?
Fryefield, K., & Shad, M. U. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.08.004 · Cited by 3
Consenso argentino sobre diagnóstico y tratamiento de la esquizofrenia resistente al tratamiento
Corral, R. M. (2021) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v32i154.119 · Cited by 18
Pharmacotherapy for bipolar disorder in adults with high-functioning autism
Amadori, S., Barbuti, M., & Perugi, G. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138332 · Cited by 4
SECOND TO NONE – RATIONALE, TIMING, AND CLINICAL MANAGEMENT OF CLOZAPINE USE IN SCHIZOPHRENIAPreprint
Qubad, M., & Bittner, R. A. (2022) · doi:10.31234/osf.io/jfc6w · Cited by 3
Synthesis of Phenothiazine Derivatives and their Diverse Biological Activities: A Review
Kaur, P., Utreja, D., & Sharma, S. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575405792250813070957 · Cited by 2
Chang, W.-C., Hung, D., Chen, M., Su, T., Bai, Y., Chen, Y.-Y., & Tu, P. (2026) · Psychological Medicine · doi:10.1017/s0033291726103377 · Cited by 2
“This was probably not related to the traditional hyperdopaminergic hypothesis in SZ but to a condition known as medication-induced supersensitivity (Chouinard et al., 2017).”
Kogure, M., Kanahara, N., Kimura, M., Hanaoka, S., Hirano, H., & Iyo, M. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001564 · Cited by 2
Self-citationTakeuchi, H., & Watabe, K. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13534 · Cited by 3
Crump, C., Good, M. E., Abuelazm, H., & El‐Mallakh, R. S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208269 · Cited by 4
Kim, D. D., Procyshyn, R., Jones, A. A., Gicas, K., Jones, P. W., Petersson, A. M., Lee, L.-H. N., McLellan-Carich, R., Cho, L. L., Panenka, W., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.01.003 · Cited by 3
Schmitz, C. N., Hart, X. M., Spangemacher, M., Roth, J. L., Lazarevic, I., Oberthür, G., Büsing, K. A., Becker, R., Cumming, P. D., & Gründer, G. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104094 · Cited by 3
“Furthermore, prolonged treatment with antipsychotic medication can increase receptor binding (Silvestri et al., 2000), which might propagate to hemodynamic changes, perhaps as a marker for the emergence of receptor supersensitivity (Chouinard et al., 2017).”
Bressan, G. N., Rodrigues, T., da Silva, M. E. B., Schetinger, M. R. C., Scussel, R., Machado‐de‐Ávila, R. A., Abel, J. D. S., & Fachinetto, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04275-w · Cited by 4
“However, the dopaminergic system seems to be central to the pharma - cological action and adverse effects of antipsychotics and the main hypothesis for TD continues to be dopaminergic supersensitivity [ 11, 12 ].”
da Rosa, J. L. O., Brivio, P., Rossato, D. R., Fontoura, M. B., de Souza, L. E. M., Fumagalli, F., Calabrese, F., & Bürger, M. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111376 · Cited by 2
Servonnet, A., Allain, F., Gravel-Chouinard, A., Hernández, G., Caporuscio, C. B., Legrix, M., Lévesque, D., Rompré, P.-P., & Samaha, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108747 · Cited by 3
“Antipsychotic-induced dopamine supersensitivity is linked to antipsychotic treatment failure and to an exacerbation of psychosis symptoms (Asper et al., 1973; MØller Nielsen et al., 1974; Chouinard et al., 1978; Margolese et al., 2002; Chouinard and Chouinard, 2008; Fallon and Dursun, 2011; Iyo et al., 2013; Gill et a…”
BackgroundSelf-citationSuicidality and psychotic episodes after starting aripiprazole: two case reports
Meyer, G., Faria, C. G. F., Beck, M., Riutort, M., Michel, B., & Javelot, H. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000408 · Cited by 2
“Indeed, the dopaminergic supersensitivity induced during a long-term exposure to a high-potency D 2 antagonist (risperidone/ paliperidone) is a potential common pathway to understand the behavioral reactions observed after aripiprazole exposure (Chouinard et al., 2017).”
BackgroundInfluentialPeretti, C.-S., & Chouinard, G. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000501130 · Cited by 2
Self-citationContinuing Antipsychotic Medication for Patients With Psychotic Depression in Remission
Munkholm, K., Jørgensen, K. J., & Paludan‐Müller, A. S. (2019) · JAMA · doi:10.1001/jama.2019.17691 · Cited by 2
Individualizing tapering antipsychotic schemes considering D2 blockade dynamics
Costardi, C. G., Gadelha, A., & Bressan, R. A. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211000780 · Cited by 2
“In addition, although some antipsychotics have lower D2 affinity, such as quetiapine and clozapine, their short half-lives may be associated with withdrawal symptoms, including rebound psychosis, also demanding slower tapering (Chouinard et al., 2017).”
BackgroundNeurological Disorders: Biochemistry of Drug Resistance and Future Challenges
Ahmad, M. S., Batool, S., Islam, A., Jabeen, A., Noureen, A., SHAMSHAD, S., Zainab, T., Shahid, M., & Ahmed, W. (2021) · Springer eBooks · doi:10.1007/978-3-030-76320-6_9 · Cited by 4
Supersensitivity Psychosis with Acute Dystonia
Nunez, T., Meyerson, G., Alani, M., et al. (2023) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1465 · Cited by 2
Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)
Uchida, H., Kim, E., Jarskog, L. F., Fleischhacker, W. W., Remington, G. J., & Lieberman, J. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_134-1 · Cited by 2
Antipsychotics Circa 2020: What are we thinking?
Remington, G. J., & Kapur, S. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108181 · Cited by 2
C.04.02 When the drugs stop working
Samaha, A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.980 · Cited by 1
Self-citationTAKANO, S., Hashimoto, T., Hayatsu, R., Kanahara, N., & Nakazato, M. (2025) · Cureus · doi:10.7759/cureus.93361 · Cited by 3
“Neurological signs of the DS state include tardive dyskinesia and withdrawal dyskinesia [4,5].”
Self-citationNarcolepsy Associated With Streptococcal Infection: A Case Report and Literature Review
Zhu, Z., Zhang, Q., Hu, S., Yan, C., Jiang, W., & Ji, Y. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71512 · Cited by 1
“One plausible explanation is that prolonged exposure to high-dose antipsychotic therapy may induce dopamine receptor hypersensitivity, known as dopamine supersensitivity psychosis (DSP), which could perpetuate or exacerbate psychotic symptoms in vulnerable individuals [15].”
Vadiei, N., & Crismon, M. L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1736922 · Cited by 1
“Furthermore, it has been claimed that as many as 70% of patients with TRS may have dopamine supersensitivty psychosis (4), supporting the need to explore the impact of novel treatments with non-dopaminergic mechanisms of action.”
Okada, K., Kanahara, N., Otsuka, Y., Kobayashi, R., Yamanaka, H., Takaoki, Y., Ito, F., Komatsu, H., Yoshida, T., Kikuchi, Y., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.05.019 · Cited by 1
Self-citationEserian, J. K., de Oliveira, F. F., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10663 · Cited by 1
Grace, A. A., & Uliana, D. L. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.010 · Cited by 1
Louie, K., Jauhar, S., Rubio, J., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00225-7 · Cited by 2
Antipsychotics: Clinical Effectiveness
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_16 · Cited by 1
Antipsychotics: Motor Side Effects
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_14 · Cited by 1
Evidence of new-onset depression among persons with migraine after discontinuing antidepressants
Kious, B. M., & Bakian, A. V. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112990 · Cited by 1
Metadata
- Authors
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- McLean Hospital (US)
- Chiba University (JP)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 86
- Issue
- 4
- Pages
- 189-219
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2701376032
- Cited by
- 270
- References
- 221
- Citations by year
- 2026: 29 · 2025: 19 · 2024: 32 · 2023: 36 · 2022: 29 · 2021: 39 · 2020: 29 · 2019: 37 · 2018: 17 · 2017: 3
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K10266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine receptor supersensitivity, tardive dyskinesia, treatment-resistant schizophrenia, psychotic relapse, atypical antipsychotics, long-acting injectable antipsychotics, prolactin, drug-induced movement disorders
- MeSH terms
- Brain, Dopamine, Humans, Psychoses, Substance-Induced, Antipsychotic Agents, Receptors, Dopamine D2, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.